

Supplementary Table S1. Clinical and demographic data of Kidney transplanted patients

Patient	Age	Sex	PD	Immunosuppression	Months after Tx	Associated Diseases	DD (mg)	ATH	LLM	BMI
P1	21	M	Ind N	Str/Rapa	12	-	2	-	-	18,04
P2	53	M	CN	Str/FK	156	T2D/HBP	1	-	-	29,7
P3	35	F	TIN	FK /AZA	120	-	-	-	-	18,3
P4	47	M	Ind N	Str/CsA /MMF	60	HU/HBP	1	-	-	31,7
P5	67	M	CRAN	Str/FK /MMF	264	HU/HBP/DysLP	1	CEI	-	26,5
P6	37	M	-	Str/FK /MMF	84	HU/HBP/NCA	1	CEI/CCB	CLS	28,08
P7	37	M	CRAN	FK /MMF	60	-	4	CEI	-	26,9
P8	66	M	VN	Str/FK /MMF	72	HBP/H Str	4	CCB	-	26,3
P9	48	F	Ind N	Str/FK /AZA	96	-	-	-	-	16,13
P10	18	F	CTIN	Str/FK	24	Car S	4	-	-	19,2
P11	29	M	Ind N	Str/FK /MMF	144	-	2	-	-	15,8
P12	58	M	IN	Str/FK /MMF	96	HU/HBP	5	CCB/BB	-	24,48
P13	33	F	SLE	Str/FK /MMF	12	DysLP	-	-	-	19,9
P14	56	M	Ind N	Str/FK /MMF	72	T2D/HBP/NCA/DysLP	-	CEI/CCB/BB	CLS	30,8
P15	39	M	-	Str/FK /MMF	48	T2D/HBP/DysLP	-	CEI/CCB	LovaCLS	27,5
P16	57	M	CRAN	Str/FK /AZA	72	DysLP	6	CEI	Lip	23,5
P17	53	M	Ind N	Str/FK /MMF	84	T2D/HBP/NCA	-	CEI/CCB	CLS	32,5
P18	51	M	DN	Str/CsA /MMF	84	T2D/HBP/DysLP	225	CCB/BB	Lip	24,5
P19	46	M	Ind N	Str/FK /MMF	96	DysLP	3	CEI/CCB	CLS	24,2
P20	36	F	Ind N	Str/FK /MMF	156	HBP/DysLP	5	CEI/CCB/BB	Lip	-
P21	60	F	CGN	Str/FK /AZA	60	T2D/DysLP	-	-	-	37,7
P22	17	M	TIN	Str/FK /MMF	108	-	3	-	Lip	20,7
P23	26	M	-	Str/FK /MMF	12	-	-	-	-	20,3
P24	42	F	CGN	Str/FK /AZA	36	-	-	-	-	32
P25	43	F	CGN	Str/CsA /AZA	168	-	-	-	-	29,9
P26	42	F	Ind N	Str/FK /MMF	-	HBP	-	-	-	25,5
P27	50	F	SLE	Str/FK /MMF	120	-	5	CCB/BB	-	32,6
P28	41	M	Ind N	Str/FK /MMF	36	SNHL	-	CEI/CCB	-	24,6
P29	27	M	Ind N	FK /AZA	96	NCA	-	CEI	-	19,9

<b>P30</b>	61	M	-	Str/CsA /MMF	216	HBP/CAD	-	CEI/CCB/BB	-	27,3
<b>P31</b>	43	F	Ind N	Str/FK /AZA	144	HU	-	-	CLS	-
<b>P32</b>	37	M	TIN	Str/FK /MMF	8	HBP	-	CCB/BB	-	21,3
<b>P33</b>	30	M	Ind N	Str/FK /MMF	3	T2D/DysLP	-	-	-	-
<b>P34</b>	50	M	VN	Str/FK /MMF	84	T2D/HBP/DysLP	-	CCB/BB	Lip	27,16
<b>P35</b>	41	M	GN	Str/FK /MMF	132	T2D/DysLP	-	-	CLS	-
<b>P36</b>	30	M	Ind N	Str/Rapa	7	-	-	-	CLS	-
<b>P37</b>	39	M	Ind N	Str/FK /MMF	10	DysLP	-	-	-	23,18
<b>P38</b>	47	M	IN	Str/CsA /MMF	216	H Str	225	-	Lip	26,5
<b>P39</b>	42	F	-	Str/FK /MMF	120	HBP/NCA	-	CEI/CCB	-	25,4
<b>P40</b>	44	M	VN	Str/FK /MMF	108	HBP/DysLP	-	CEI/CCB	-	23,6

PD = Ind N: Indeterminate Nephropathy; CGN: chronic glomerulonephritis; GN: glomerulonephritis; SLE: Lupus nephritis; TIN: tubulointerstitial Nephritis; CTIN: chronic tubulointerstitial Nephritis; IN: Interstitial Nephritis; CN: chronic nephropathy; CRAN:chronic renal allograft nephropathy; VN: vascular nephropathy. Immunosuppression = Str: steroids Rapa:Rapamicin (Sirolimus); FK: Tacrolimus ; CsA:cyclosporin; MMF: mecophenolate mofetil ; AZA: Azathioprine. AD = T2D: type 2 Diabetes; HPB: hyper blood pressure; HU: hyperuricemia; DysLP: Dyslipidemia;HStr: Hemorrhagic stroke; SNHL: Sensorineural hearing loss; NCA: Neurocirculatory asthenia; CAD: coronary artery disease. DD = Daily dose of (CsA, FK, Rapa). AHT = Antihypertensives; CEI: angiotensin-converting enzyme inhibitor ; CCB: calcium channel blockers; BB: Beta blockers. LLM = Lipid lowering medications; CLS: statin;LovaCLS: lovastatin; LIP: lipanthyl




Figure S1: OPLS-DA score plots of the fecal metabolic profiles from the KT sub-groups with different graft periods: OPLS-DA scores plot model showing no discrimination between the different groups based on all extraction methods with  $R^2(X) = 0.32$ ,  $R^2(Y) = 0.415$ ,  $Q^2 = 0.236$ , and cross validated analysis of variance (CV-ANOVA)  $p = 0.601$ . Red circles represent patients with short-period graft (SG); Green circles represent patients with long-period graft (LG); Yellow circles represent patients with medium-period graft (MG); and Blue circles represent the healthy subjects (T Group).